$1.84
6.36% yesterday
Nasdaq, Sep 27, 10:03 pm CET
ISIN
US56854Q1013
Symbol
MRNS
Sector
Industry

Marinus Pharmaceuticals Inc Stock price

$1.84
+0.37 25.17% 1M
-7.01 79.21% 6M
-9.03 83.07% YTD
-6.16 77.00% 1Y
-10.51 85.10% 3Y
-4.24 69.74% 5Y
-26.12 93.42% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.11 6.36%
ISIN
US56854Q1013
Symbol
MRNS
Sector
Industry

Key metrics

Market capitalization $95.30m
Enterprise Value $126.51m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.18
P/S ratio (TTM) P/S ratio 3.15
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 16.56%
Revenue (TTM) Revenue $30.26m
EBIT (operating result TTM) EBIT $-133.19m
Free Cash Flow (TTM) Free Cash Flow $-120.62m
Cash position $64.68m
EPS (TTM) EPS $-2.66
P/E forward negative
P/S forward 2.59
EV/Sales forward 3.44
Short interest 4.99%
Show more

Is Marinus Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Marinus Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Marinus Pharmaceuticals Inc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Marinus Pharmaceuticals Inc forecast:

Buy
80%
Hold
20%

Financial data from Marinus Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
30 30
17% 17%
100%
- Direct Costs 3.42 3.42
109% 109%
11%
27 27
10% 10%
89%
- Selling and Administrative Expenses 65 65
12% 12%
215%
- Research and Development Expense 95 95
6% 6%
312%
-133 -133
8% 8%
-438%
- Depreciation and Amortization 0.58 0.58
18% 18%
2%
EBIT (Operating Income) EBIT -133 -133
8% 8%
-440%
Net Profit -149 -149
439% 439%
-493%

In millions USD.

Don't miss a Thing! We will send you all news about Marinus Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Marinus Pharmaceuticals Inc Stock News

Neutral
Business Wire
8 days ago
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today is hosting an Investor and Analyst Day and will present an in-depth review of the Company's development program for ZTALMY® (ganaxolone) oral suspension CV in tuberous sclerosis complex (TSC) ahead of the P...
Neutral
Business Wire
16 days ago
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced agenda topics and speakers for its upcoming Investor & Analyst Day on Friday, September 20 from 9:00 a.m. to 12:00 p.m. ET in New York. The event will feature presentations from Marinus' leadershi...
Neutral
Business Wire
about one month ago
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host an Investor and Analyst Day on Friday, September 20 from 9:00 a.m. to 12:00 p.m. Eastern Time in New York and via webcast. The event will feature presentations from Marinus management and key opinion le...
More Marinus Pharmaceuticals Inc News

Company Profile

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Head office United States
CEO Scott Braunstein
Employees 165
Founded 2003
Website www.marinuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today